Fermenta Biotech Navigates Q3FY26 with Robust 9-Month Growth and Strategic Innovation

Fermenta Biotech Limited, a key player in nutritional ingredients, has presented a mixed but ultimately strong financial picture for Q3 and the nine-month period ending FY26. While the third quarter saw a moderation in EBITDA and Profit After Tax (PAT) year-on-year, largely attributed to a significant non-recurring real estate income in the previous fiscal year, the company's consolidated 9-month performance paints a compelling story of structural growth and operational resilience. For the nine-month period, Fermenta reported a robust 25% year-on-year increase in revenue, reaching INR 421.2 crore. This was complemented by a 20% rise in both EBITDA and PAT, underscoring the underlying strength of its diverse business segments.

The company's performance highlights a strategic focus on high-growth areas and operational efficiencies. The human nutrition segment, particularly Vitamin D3, continues to be a dominant revenue driver, contributing significantly to the overall top line. Both human and animal nutrition segments demonstrated impressive volume growth, with human nutrition volumes up 46% and animal nutrition volumes up 52% over 9MFY25. This indicates strong market penetration and demand for Fermenta's core offerings. Furthermore, the German toll manufacturing subsidiary emerged as a significant growth engine, recording a remarkable 147% year-on-year revenue increase to INR 65.4 crore and a 28% rise in EBITDA to INR 11.2 crore for 9MFY26. The green chemistry segment also showed promising traction, with sales in 9M FY26 already surpassing the full-year FY25 figures, reaching INR 9 crore compared to INR 7 crore previously.

Despite the strong overall performance, the company did face some specific challenges. The US trading business subsidiary reported an EBITDA loss of INR 1.1 crore for 9MFY26, a notable shift from a profit of INR 1.6 crore in the prior year. Additionally, the animal nutrition segment experienced an 8% decline in average realization over 9MFY25, suggesting pricing pressures in that market. A one-time, exceptional expense of INR 2.19 crore was also incurred in Q3FY26 due to new Labour Codes notified by the Government of India, impacting the quarter's profitability. However, these specific headwinds were largely offset by the robust performance across other segments and the company's disciplined cost management.

Fermenta's commitment to operational excellence is evident in its optimized cost structure. Raw material costs remained stable at 38% of revenue in 9MFY26, consistent with FY25, and significantly improved from 53% in FY24, reflecting better procurement and input pricing. Employee costs were optimized at 15% of revenue, unchanged from FY25 and sharply down from 22% in FY24, demonstrating effective operating leverage. Manufacturing expenses also trended lower to 11% in 9MFY26 from 15% in FY25, indicating improved production efficiency. Furthermore, finance costs were reduced to 2% from 3% in FY25, highlighting successful deleveraging and a healthier balance sheet.

Looking ahead, Fermenta Biotech is strategically positioned to capitalize on evolving consumer needs and regulatory requirements across diverse markets. The company's R&D focus includes the commercialization of Calcefediol, development of Vitamin D3 analogs, and expansion into a new lipase portfolio for biotechnology applications. Its strategic product portfolio, featuring patented Spray-Dried Vitamin D3 and plant-based VITADEET™ Green, aims to drive future revenue growth by targeting vegan supplement markets and offering clean-label solutions. Through strategic partnerships with organizations like Abbott, NIFTEM, and the Global Alliance for Improved Nutrition (GAIN), Fermenta is amplifying its market reach, enhancing technical capabilities, and strengthening its industry influence, particularly in food fortification initiatives like the WFP FRK premix development. This integrated approach, combining robust operational performance with continuous innovation and strategic collaborations, positions Fermenta Biotech for sustained growth and value creation in the nutritional and chemical solutions space.